Valiant Labs Receives GST Order Demanding ₹62.97 Lakhs, Including Penalty
Valiant Laboratories Limited received a GST order demanding ₹57.25 Lakhs for wrongly availed Input Tax Credit on capital goods for FY 2021-22. The company faces a total demand of ₹62.97 Lakhs, including a penalty of ₹5.72 Lakhs. The company is evaluating options to appeal the order.
The total demand of ₹62.97 Lakhs, while not extremely material for a listed company, could impact short-term financials and requires the company to engage in appeals, thus having a medium impact.
The company has received an order from the CGST & Central Excise office demanding a significant amount towards tax and penalty due to alleged wrong availment of Input Tax Credit.
Valiant Laboratories Limited has received an order dated December 26, 2025, from the Office of the Assistant Commissioner of CGST & Central Excise, Navi Mumbai. The order pertains to the wrong availment of Input Tax Credit (ITC) on capital goods for the Financial Year 2021-22.
The company had claimed depreciation on the GST component of capital goods, which the authority has deemed impermissible. This has resulted in a determination of wrongly availed ITC at ₹57,24,953.
The alleged violations include the disallowance of ITC on capital goods due to non-fulfilment of conditions and the claim of depreciation on the tax component, reportedly in violation of Sections 16(2), 17(5), 73, 50, and 122(2)(a) of the CGST Act, 2017, read with applicable provisions of the IGST and MGST Acts. The period for which this communication is applicable is April 2021 to March 2022.
The financial impact includes a tax demand of ₹57,24,953 and a penalty of ₹5,72,494, aggregating to a total of ₹62,97,447. Valiant Laboratories Limited is currently evaluating all available options, including the filing of an appeal against this order before the appropriate authority.
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.